Navigation Links
Newer Drug-Releasing Stent Cuts Chances of Cardiac Events: Study
Date:8/21/2012

TUESDAY, Aug. 21 (HealthDay News) -- A newer generation, drug-releasing stent led to fewer adverse cardiac events, such as heart-related death or heart attack linked to the same artery, than bare metal stents did among heart attack patients, a new study shows.

Stents are tiny mesh tubes surgically implanted to open arteries.

Swiss researchers noted the newer drug-emitting stents may also help patients avoid the chronic inflammation associated with early-generation drug-releasing stents.

"Newer-generation drug-eluting stents with biodegradable polymers provide controlled drug release," the study authors explained in the Aug. 22/29 issue of the Journal of the American Medical Association.

Led by Dr. Lorenz Raber, of Bern University Hospital, the research team compared the safety and effectiveness of stents that released the drug biolimus from a biodegradable polymer, against bare metal stents that did not release a drug.

The study involved almost 1,200 patients in Europe and Israel who had a type of heart attack known as ST-segment elevation myocardial infarction (STEMI). Nearly 80 percent of the patients were men, and the average age was 61 years.

The participants were randomly assigned to receive the drug-releasing stent or the bare metal stent. They were examined one month after their artery opening procedure, and again at 12 months. The researchers determined the effectiveness of the stents by measuring rates of adverse cardiac events, including cardiac death and other heart problems.

The investigators found that at one year, 4.3 percent of patients who received the drug-releasing stents experienced major adverse cardiac events, compared to 8.7 percent of patients who received bare metal stents.

These findings represent a significant 4.4 percent absolute reduction and 51 percent relative reduction in the risk for major adverse cardiac events, the researchers pointed out in a journal news release.

Use of the new drug-releasing stent also resulted in reduced risk for cardiac death. At one year, rates of clotting within the stent were about 1 percent among patients with the drug-releasing stents, compared to just over 2 percent among patients who received bare metal stents.

"Our results suggest better clinical outcomes in terms of major adverse cardiac events of a stent releasing biolimus from a biodegradable polymer compared with a bare metal stent for the treatment of patients with STEMI," the study authors concluded.

Another expert agreed.

"Newer generation drug-eluting stents which are currently FDA-approved in the United States have been shown to be superior to bare metal stents in decreasing event rates at one year when used for [heart attack]," said Dr. Barry Kaplan, vice chairman of cardiology at North Shore University Hospital in Manhasset, N.Y. "This trial is further proof that drug-eluting stents used in heart attack patients lead to superior results," he added.

And Kaplan noted that, compared to bare metal stents, the drug-releasing models had fewer dangerous events at one year, including re-closure of the artery or clotting within the stent.

But, he added one caveat.

"The relative comparison between the biolimus-coated stent used in this study versus [other] currently available second-generation drug-eluting stents [available in the United States] still needs to be determined," Kaplan said.

More information

The U.S. National Library of Medicine has more about stents.

-- Mary Elizabeth Dallas

SOURCES: Barry Kaplan, M.D., F.A.C.C., vice chairman, cardiology, North Shore University Hospital, Manhasset, N.Y., and Long Island Jewish Medical Center, New Hyde Park, N.Y.; Journal of the American Medical Association, news release, Aug. 21, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer Antidepressants May Be Safe for Parkinsons Patients
2. Newer Second-Line Diabetes Drug May Outperform Older Meds
3. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
4. Newer technology to control blood sugar works better than conventional methods
5. Newer hip reconstruction technique provides good outcomes for athletes
6. Newer Bone Drug Better for Advanced Breast Cancer Patients: Study
7. Older Antipsychotics May Work as Well as Newer Ones: Review
8. Newer Psoriasis Drugs May Lower Heart Attack Risk for Patients
9. Dissolvable Heart Artery Stents Appear Safe in Study
10. Life-saving primary PCI rising in Stent for Life countries
11. Baseline characteristics of children with mild persistent asthma predict response to ICS
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Drug-Releasing Stent Cuts Chances of Cardiac Events: Study
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices ... But this approach has proven transformative, both for people who hear voices and for ... is used around the world, but it still lags in the United States. , ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... commercial molecular diagnostics device that enables unprecedented portability and convenience. , The Cube ... four inches cubed in size, the Cube fits easily into any space, whether ...
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... WaterField ... for digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ... waxed canvas or ballistic nylon, the Duo is smartly designed for Dad’s ...
(Date:5/31/2016)... ... , ... Phynd Technologies, Inc. announced recently the signing of three new hospitals: ... Medical Center – Somers Point, NJ. The new clients range in bed size from ... of Phynd’s solution and its interoperability. , Houston Methodist is a leading academic medical ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... firm and statement solutions provider, for the tenth consecutive year as a ... issue of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 31, 2016 Diplomat Pharmacy, Inc. (NYSE: ... conversation slated for June 7, 2016, to take a closer ... noon to 1 p.m. ET, will focus on a man ... the road to wellness. The event is ... patients and health care professionals, talking about triumphs and the ...
(Date:5/31/2016)... May 31, 2016   Plexus Technology Group, ... anesthesia information management systems (AIMS), is pleased to ... as Vice President of Technology. In this new ... aspects of the company,s technological development. He will ... to determine the expansion of new products, product ...
(Date:5/31/2016)... York , May 31, 2016 ... essential ingredient in food, cosmetics and pharmaceuticals, with global ... revenues worth US$ 1.6 Bn. Demand for ... products, juices, and yogurts will continue its upward momentum ... trend will also boost positive sentiment on aloe vera, ...
Breaking Medicine Technology: